Equity Profile
Pre-Earnings Brief
Kymera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for various diseases....
Earnings Per Share (EPS)
EPS is a key indicator of a company's profitability and will show how well Kymera is managing its expenses relative to its revenue.
Revenue Growth
Although revenue estimates are not available, any indication of revenue growth would signal market acceptance of its therapies.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
1Q
EPS Beat Rate
50%
Avg EPS Surprise
-4.04%
Avg Stock Reaction
-3.15%
In Q1 2026, Kymera reported an EPS of -$0.71, beating expectations by 20.4%. However, the stock fell 0.54% the following day, indicating mixed market reactions.
Management Promises & Guidance
Overall, expectations for Kymera's upcoming earnings are uncertain due to a lack of analyst estimates and management guidance.
Bull Case
If Kymera can demonstrate significant progress in its drug pipeline or better-than-expected R&D efficiency, it could lead to positive investor sentiment and stock appreciation.
Bear Case
Conversely, if the company fails to show progress or reports wider losses than anticipated, it could lead to a decline in stock price.
Earnings Per Share (EPS)
N/AEPS is a key indicator of a company's profitability and will show how well Kymera is managing its expenses relative to its revenue.
Revenue Growth
N/AAlthough revenue estimates are not available, any indication of revenue growth would signal market acceptance of its therapies.
R&D Spending
N/AResearch and development spending is crucial for biotech firms like Kymera, as it reflects their commitment to innovation and future product pipelines.
Expectations
The print will turn on these two things.
Q1
What is the current status of Kymera's drug pipeline and any upcoming clinical trial results?
Investors will closely watch for updates on drug development as this can significantly impact future revenue potential.
Q2
How much is Kymera investing in R&D this quarter?
R&D spending is critical for biotech firms; higher spending may indicate confidence in future product success.
Edge
Why consensus could be wrong
The Street may be underestimating the potential for Kymera's drug pipeline to yield positive results sooner than expected, given recent advancements in biotech.
Supporting Evidence
The options market is pricing in a 26.89% move, indicating higher volatility expectations than historical averages.
Insider selling of $2.1 million could suggest a lack of confidence in the near-term performance.
Key Risk
If R&D spending shows a marked increase without corresponding revenue growth, it could challenge the current market consensus.
Edge
Pre-commit to what would confirm each case.
This quarter's performance is under scrutiny as investors assess Kymera's ability to manage costs while advancing its drug pipeline.
Bull Confirmed If
A reduction in EPS loss to below -$0.60 would confirm the bull case.
Bear Confirmed If
An EPS loss greater than -$0.80 would confirm the bear case.
Pre-Earnings Positioning
Implied Move
±26.89%
Historical Avg
±4.4%
The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings report.
Options are pricing ±26.9% while KYMR has averaged ±4.4% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
38.7%
Edge
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$2.1M
23,692 sh
3 insiders
Net
$2.1M
Net selling
Most Active Insiders· 11 open-market trades
$1.4M
Net selling
$616,598.40
Net selling
$121,230.00
Net selling
Recent Transactions
Apr 22, 2026 · @ $89.96
5,900 sh
$530,764.00
Apr 14, 2026 · @ $90.00
5,251 sh
$472,598.40
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Kymera beats expectations, history suggests a potential stock increase of around 2.16%, confirming positive market sentiment.
In-Line / Cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity from management.
Miss
Should Kymera miss expectations, history suggests a potential decline of around 4.14%, reflecting investor disappointment.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Summit Therapeutics Inc.
Apr 14, 2026 · @ $89.97
4,159 sh
$374,185.23
Apr 15, 2026 · @ $90.10
2,750 sh
$247,775.00
Apr 15, 2026 · @ $89.95
2,200 sh
$197,890.00